 <h1>Cobimetinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of cobimetinib include:</b> skin photosensitivity. <b>Other side effects include:</b> increased creatine phosphokinase in blood specimen.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cobimetinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cobimetinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cobimetinib:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>bleeding gums</li>
<li>blurred vision or any other change in vision</li>
<li>chest discomfort or pain</li>
<li>chills</li>
<li>clay colored stools</li>
<li>coughing up blood</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>faintness</li>
<li>fast irregular or pounding heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>muscle cramps or spasms</li>
<li>muscle pain or stiffness</li>
<li>nausea and vomiting</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>paralysis</li>
<li>pounding in the ears</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>redness or other discoloration of the skin</li>
<li>seeing flashes or sparks of light</li>
<li>seeing floating spots before the eyes, or a veil or curtain appearing across part of vision</li>
<li>severe sunburn</li>
<li>slow or fast heartbeat</li>
<li>swelling of the feet or lower legs</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cobimetinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acne or pimples</li>
<li>diarrhea</li>
<li>nausea</li>
<li>swelling or inflammation of the mouth</li>
<li>vomiting</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cobimetinib: oral tablet</i></p><h3>General</h3><p>The most commonly reported adverse reactions (more than 35%) were increased creatinine, increased CPK, lymphopenia, increased AST, increased alkaline phosphatase, increased ALT, hypophosphatemia, anemia, increased gamma-glutamyltransferase, diarrhea, photosensitivity reactions, hypoalbuminemia, nausea, and hyponatremia.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (99.6%) Common (1% to 10%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Increased CPK (79%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (73%), increased alkaline phosphatase (71%), increased ALT (68%), increased gamma-glutamyltransferase (65%)</p>
<p><b>Frequency not reported</b>: Increased total bilirubin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (73%), anemia (69%), thrombocytopenia (18%), hemorrhage (e.g., rectal, hemorrhoidal, GI tract, uterine, vaginal, pulmonary, cerebral, subarachnoid, ocular, eye, conjunctival, retinal, reproductive system, melena, hematemesis, hematochezia, gingival bleeding, metrorrhagia, hemorrhagic ovarian cyst, menometrorrhagia, menorrhagia, hemoptysis, subgaleal hematoma, hematuria, epistaxis, contusion, traumatic hematoma, ecchymosis, purpura, nail bed bleeding)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Dehydration, hypophosphatemia (68%), hypoalbuminemia (42%), hyponatremia (38%), hyperkalemia (26%), hypokalemia (25%), hypocalcemia (24%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (60%), nausea (41%), vomiting (24%), stomatitis (14%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Photosensitivity reactions (46%), acneiform dermatitis (16%), alopecia (15%), hyperkeratosis (11%), erythema (10%), maculopapular rash, dermatitis acneiform rash<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (28%), hemorrhage (13%), chills (10%) Common (1% to 10%):<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Decreased LVEF (26%), hypertension (15%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Vision impaired (e.g., vision blurred, visual acuity reduced, visual impairment) (15%), chorioretinopathy (e.g., retinal detachment, detachment of retinal pigment epithelium, detachment of macular retinal pigment epithelium) (13%), retinal detachment (e.g., retinal detachment, detachment of retinal pigment epithelium, detachment of macular retinal pigment epithelium) (12%)</p>
<p><b>Common</b> (1% to 10%): Serious retinopathy (chorioretinopathy, retinal detachment)</p>
<p><b>Frequency not reported</b>: Retinal vein occlusion<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Cutaneous squamous cell carcinoma/keratoacanthoma, basal cell carcinoma</p>
<p><b>Uncommon</b> (0.1% to 1%): Second primary melanoma, non-cutaneous malignancies<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about cobimetinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cobimetinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Cotellic</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Melanoma, Metastatic</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cobimetinib: oral tablet</i></p><h3>General</h3><p>The most commonly reported adverse reactions (more than 35%) were increased creatinine, increased CPK, lymphopenia, increased AST, increased alkaline phosphatase, increased ALT, hypophosphatemia, anemia, increased gamma-glutamyltransferase, diarrhea, photosensitivity reactions, hypoalbuminemia, nausea, and hyponatremia.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (99.6%) Common (1% to 10%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Increased CPK (79%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (73%), increased alkaline phosphatase (71%), increased ALT (68%), increased gamma-glutamyltransferase (65%)</p><p><b>Frequency not reported</b>: Increased total bilirubin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphopenia (73%), anemia (69%), thrombocytopenia (18%), hemorrhage (e.g., rectal, hemorrhoidal, GI tract, uterine, vaginal, pulmonary, cerebral, subarachnoid, ocular, eye, conjunctival, retinal, reproductive system, melena, hematemesis, hematochezia, gingival bleeding, metrorrhagia, hemorrhagic ovarian cyst, menometrorrhagia, menorrhagia, hemoptysis, subgaleal hematoma, hematuria, epistaxis, contusion, traumatic hematoma, ecchymosis, purpura, nail bed bleeding)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Dehydration, hypophosphatemia (68%), hypoalbuminemia (42%), hyponatremia (38%), hyperkalemia (26%), hypokalemia (25%), hypocalcemia (24%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (60%), nausea (41%), vomiting (24%), stomatitis (14%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Photosensitivity reactions (46%), acneiform dermatitis (16%), alopecia (15%), hyperkeratosis (11%), erythema (10%), maculopapular rash, dermatitis acneiform rash<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (28%), hemorrhage (13%), chills (10%) Common (1% to 10%):<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Decreased LVEF (26%), hypertension (15%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Vision impaired (e.g., vision blurred, visual acuity reduced, visual impairment) (15%), chorioretinopathy (e.g., retinal detachment, detachment of retinal pigment epithelium, detachment of macular retinal pigment epithelium) (13%), retinal detachment (e.g., retinal detachment, detachment of retinal pigment epithelium, detachment of macular retinal pigment epithelium) (12%)</p><p><b>Common</b> (1% to 10%): Serious retinopathy (chorioretinopathy, retinal detachment)</p><p><b>Frequency not reported</b>: Retinal vein occlusion<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Cutaneous squamous cell carcinoma/keratoacanthoma, basal cell carcinoma</p><p><b>Uncommon</b> (0.1% to 1%): Second primary melanoma, non-cutaneous malignancies<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA. </p><h2>More about cobimetinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cobimetinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Melanoma, Metastatic</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>